Epidemiology and risk factors for late infection in solid organ transplant recipients

Transplant Infectious Disease

Volumn 13, Issue 6, 2011, Pages 598-607

  Cervera, C ^a   Fernandez Ruiz M ^a   Valledor, A ^a   Linares, L ^a   Anton A ^a   Angeles Marcos M ^a   Sanclemente, G ^a   Hoyo, I ^a   Cofan F ^a   Ricart, M J ^a   Perez Villa F ^a   Navasa, M ^a   Pumarola, T ^a   Moreno, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Epidemiology; Late infection; Outcome; Risk factors; Solid organ transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; AZTREONAM; CEFAZOLIN; CEFOTAXIME; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; TEICOPLANIN; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; EPIDEMIC; FEMALE; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RISK FACTOR; SEPSIS; SURVIVAL; URINARY TRACT INFECTION;

ADULT; BACTERIAL INFECTIONS; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PARASITIC DISEASES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; VIRUS DISEASES;

EID: 80051998310     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00646.x     Document Type: Article

References (27)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
2. Linares L, Cofán F, Cervera C, et al. Infection-related mortality in a large cohort of renal transplant recipients. Transplant Proc 2007; 39: 2225-2227.
3. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host (4th edn). New York: Kluwer Academic/Plenum Publishers, 2002: 573-679.
4. Garrido RS, Aguado JM, Díaz-Pedroche C, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82: 1457-1462.
5. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7: 964-971.
6. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34: 347-351.
7. Gayowski T, Marino IR, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998; 65: 499-504.
8. Neuberger J. Liver transplantation. J Hepatol 2000; 32: 198-207.
9. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001; 181: 475-479.
10. Moreno Planas JM, Rubio González E, Herreros de Tejada A, et al. Late mortality in patients with liver transplantation: causes and risk factors. Transplant Proc 2003; 35: 707-708.
11. Aguado JM, Torre-Cisneros J, Fortún J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-1284.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
13. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
14. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
15. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33: 629-640.
16. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-1665.
17. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195-200.
18. Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL. Rates of first infection following kidney transplant in the United States. Kidney Int 2009; 75: 317-326.
19. Torres J, Aguado JM, San Juan R, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transpl Int 2008; 21: 873-878.
20. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875-878.
21. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846.
22. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390-1396.
23. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
24. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128-1134.
25. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
26. Shields PL, Tang H, Neuberger JM, Gunson BK, McMaster P, Pirenne J. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 1999; 68: 530-535.
27. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-857.